Impact of adherence to statins on chronic heart failure in primary prevention.
暂无分享,去创建一个
Lucie Blais | Anick Bérard | Lyne Lalonde | M. White | L. Blais | A. Bérard | S. Perreault | L. Lalonde | Alice Dragomir | Sylvie Perreault | A. Dragomir | Michel White
[1] A. Jánosi,et al. Rosuvastatin in older patients with systolic heart failure. , 2007, The New England journal of medicine.
[2] Sander Greenland,et al. Monte Carlo sensitivity analysis and Bayesian analysis of smoking as an unmeasured confounder in a study of silica and lung cancer. , 2004, American journal of epidemiology.
[3] A. Go,et al. Gender and risk of adverse outcomes in heart failure. , 2004, The American journal of cardiology.
[4] J. Larosa,et al. Effect of statins on risk of coronary disease: a meta-analysis of randomized controlled trials. , 1999, JAMA.
[5] B. Stricker,et al. Confounding by indication: an example of variation in the use of epidemiologic terminology. , 1999, American journal of epidemiology.
[6] S. Sunwoo,et al. Determinants of non‐compliance with lipid‐lowering therapy in hyperlipidemic patients , 2002, Pharmacoepidemiology and drug safety.
[7] D. Mozaffarian,et al. The effects of atorvastatin (10 mg) on systemic inflammation in heart failure. , 2005, The American journal of cardiology.
[8] D. Levy,et al. The epidemiology of heart failure: the Framingham Study. , 1993, Journal of the American College of Cardiology.
[9] R Peto,et al. Efficacy of cholesterol-lowering therapy in 18,686 people with diabetes in 14 randomised trials of statins: a meta-analysis. , 2008, Lancet.
[10] D. Mozaffarian,et al. Statin therapy is associated with lower mortality among patients with severe heart failure. , 2004, The American journal of cardiology.
[11] A J Belanger,et al. Epidemiology of heart failure. , 1991, American heart journal.
[12] D. Waters,et al. Effect of High-Dose Atorvastatin on Hospitalizations for Heart Failure: Subgroup Analysis of the Treating to New Targets (TNT) Study , 2007, Circulation.
[13] M. McDermott,et al. Impact of medication nonadherence on coronary heart disease outcomes. A critical review. , 1997, Archives of internal medicine.
[14] P. Giral,et al. Factors associated with low compliance with lipid‐lowering drugs in hyperlipidemic patients , 2000, Journal of clinical pharmacy and therapeutics.
[15] S. Dimauro,et al. Atorvastatin decreases the coenzyme Q10 level in the blood of patients at risk for cardiovascular disease and stroke. , 2004, Archives of neurology.
[16] Michael Böhm,et al. Statins in the Treatment of Chronic Heart Failure: A Systematic Review , 2006, PLoS medicine.
[17] A. Go,et al. Statin therapy and risks for death and hospitalization in chronic heart failure. , 2006, JAMA.
[18] S. Anker,et al. The endotoxin-lipoprotein hypothesis , 2000, The Lancet.
[19] R. Herings,et al. Adherence to evidence-based statin guidelines reduces the risk of hospitalizations for acute myocardial infarction by 40%: a cohort study. , 2006, European heart journal.
[20] Statin use and survival outcomes in elderly patients with heart failure. , 2005 .
[21] R. Tamblyn,et al. The use of prescription claims databases in pharmacoepidemiological research: the accuracy and comprehensiveness of the prescription claims database in Québec. , 1995, Journal of clinical epidemiology.
[22] J. Slattery,et al. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). 1994. , 1994, Atherosclerosis. Supplements.
[23] Femida Gwadry-Sridhar,et al. A checklist for medication compliance and persistence studies using retrospective databases. , 2007, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.
[24] R Tamblyn,et al. Using medical services claims to assess injuries in the elderly: sensitivity of diagnostic and procedure codes for injury ascertainment. , 2000, Journal of clinical epidemiology.
[25] E H Wagner,et al. A chronic disease score from automated pharmacy data. , 1992, Journal of clinical epidemiology.
[26] Rishi Sikka,et al. Estimating medication persistency using administrative claims data. , 2005, The American journal of managed care.
[27] S Greenland,et al. Sensitivity Analysis, Monte Carlo Risk Analysis, and Bayesian Uncertainty Assessment , 2001, Risk analysis : an official publication of the Society for Risk Analysis.
[28] J. Tu,et al. Class effects of statins in elderly patients with congestive heart failure: a population-based analysis. , 2008, American heart journal.
[29] Krista F Huybrechts,et al. Assessment of compliance with osteoporosis treatment and its consequences in a managed care population. , 2006, Bone.
[30] S. Lerakis,et al. Atorvastatin improves left ventricular systolic function and serum markers of inflammation in nonischemic heart failure. , 2006, Journal of the American College of Cardiology.
[31] L. Osterberg,et al. Adherence to medication. , 2005, The New England journal of medicine.
[32] S. Dimmeler,et al. Risk factors for coronary artery disease, circulating endothelial progenitor cells, and the role of HMG-CoA reductase inhibitors. , 2005, Kidney international.
[33] M. Pfeffer,et al. Ventricular Remodeling After Myocardial Infarction: Experimental Observations and Clinical Implications , 1990, Circulation.
[34] D. Levy,et al. Survival After the Onset of Congestive Heart Failure in Framingham Heart Study Subjects , 1993, Circulation.
[35] J. Foody,et al. Effect of statins, angiotensin-converting enzyme inhibitors, and beta blockers on survival in patients >or=65 years of age with heart failure and preserved left ventricular systolic function. , 2008, The American journal of cardiology.
[36] S. Yusuf,et al. Natural history and patterns of current practice in heart failure , 1993 .
[37] M. Joffres,et al. Knowledge and awareness of risk factors for cardiovascular disease among Canadians 55 to 74 years of age: results from the Canadian Heart Health Surveys, 1986-1992. , 1999, CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne.
[38] R. Bonow,et al. Chronic heart failure in the United States: a manifestation of coronary artery disease. , 1998, Circulation.
[39] Michal Abrahamowicz,et al. Comparison of nested case-control and survival analysis methodologies for analysis of time-dependent exposure , 2005 .
[40] W. Kannel,et al. Incidence and Epidemiology of Heart Failure , 2000, Heart Failure Reviews.
[41] V. Starc,et al. Atorvastatin therapy increases heart rate variability, decreases QT variability, and shortens QTc interval duration in patients with advanced chronic heart failure. , 2005, Journal of cardiac failure.
[42] R. Brook,et al. Neutral effect on markers of heart failure, inflammation, endothelial activation and function, and vagal tone after high-dose HMG-CoA reductase inhibition in non-diabetic patients with non-ischemic cardiomyopathy and average low-density lipoprotein level. , 2006, Journal of the American College of Cardiology.
[43] P. Poole‐Wilson,et al. Coronary artery disease as the cause of incident heart failure in the population. , 2001, European heart journal.
[44] Joanna M. Young,et al. Endothelium-ameliorating effects of statin therapy and coenzyme Q10 reductions in chronic heart failure. , 2005, Atherosclerosis.
[45] Elinor Miller,et al. Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR* Trial). , 2003, The American journal of cardiology.
[46] J. Cohn,et al. Statins and symptomatic chronic systolic heart failure: a post-hoc analysis of 5010 patients enrolled in Val-HeFT. , 2007, International journal of cardiology.
[47] D. J. Veldhuisen,et al. Heart failure and statins—Why do we need a clinical trial? , 2005, Zeitschrift für Kardiologie.
[48] C. Stefanadis,et al. Effects of atorvastatin on reactive hyperemia and inflammatory process in patients with congestive heart failure. , 2005, Atherosclerosis.
[49] R. Tamblyn,et al. Validation of diagnostic codes within medical services claims. , 2004, Journal of clinical epidemiology.
[50] J H Lubin,et al. Biased selection of controls for case-control analyses of cohort studies. , 1984, Biometrics.
[51] G. Fonarow,et al. Statin therapy is associated with improved survival in ischemic and non-ischemic heart failure. , 2003, Journal of the American College of Cardiology.
[52] C. Behl,et al. Selenoprotein synthesis and side-effects of statins , 2004, The Lancet.
[53] W. W. Muir,et al. Regression Diagnostics: Identifying Influential Data and Sources of Collinearity , 1980 .
[54] M. Kendrach,et al. Approximate Equivalent Rosuvastatin Doses for Temporary Statin Interchange Programs , 2004, The Annals of pharmacotherapy.
[55] F. McAlister,et al. Lipid-Lowering Therapy and Outcomes in Heart Failure , 2007, Journal of cardiovascular pharmacology and therapeutics.
[56] W. Kannel,et al. The natural history of congestive heart failure: the Framingham study. , 1971, The New England journal of medicine.